Pratia S.A.
- Address
- lock Available on a paid plan
DLBCL Clinical Research
The oncology team at Pratia S.A. focuses on Diffuse Large B-Cell Lymphoma, aiming to improve overall survival and progression‑free survival by testing new antibody‑based combinations with standard chemo‑immunotherapy.
- Evaluation of novel immunotherapy agents
- Comparison of combination regimens versus standard care
- Assessment of safety and tolerability in newly diagnosed patients
- Biomarker-driven patient stratification
- Impact on long‑term disease control
With 16 investigators overseeing five active trials, the site seeks to bring innovative treatments to patients across Europe.
Relapsed/Refractory Lymphoma Studies
In the realm of relapsed or refractory DLBCL, researchers evaluate multi‑agent strategies such as Brentuximab Vedotin combined with Lenalidomide and Rituximab to restore treatment response.
- Synergistic effects of antibody‑drug conjugates and immunomodulators
- Response rate optimization in resistant disease
- Patient‑reported outcomes and quality of life
- Exploratory biomarker analysis for predictive insight
- Comparative effectiveness against standard salvage therapy
These efforts reflect the department’s commitment to advancing care for patients who have exhausted first‑line options.
Solid Tumor Targeted Therapy Trials
Beyond lymphomas, the center conducts studies on solid tumours with specific molecular alterations, exemplified by trials of bemarituzumab in FGFR2b‑positive cancers to assess antitumor activity.
- Targeted therapy based on molecular profiling
- Preliminary efficacy evaluation in diverse solid tumor types
- Safety monitoring in early‑phase investigations
- Integration of respiratory and circulatory physiological endpoints
- Translational research linking biomarkers to clinical outcomes
The program aligns with the site’s broader focus on neoplasms and related physiological processes, supporting innovative treatment options for patients in Poland and beyond.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 25 therapeutic areas and 15 of 427 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 419 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 67 by active trials.
- 1AstraZeneca AB11active
lock +66 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB27trials
lock +50 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pratia S.A.
lock Showing 1 of 319 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 427 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 29 | Unknown | 2017-07-14 | 2026-02-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.